Abstract: The invention relates to diketopiperazine (DKP) based prodrugs. The invention also relates to the use of DKP-based prodrugs. The prodrugs comprise a pharmacological active compound, such as semaglutide, which is liberated from the prodrug upon conversion of the prodrug.
| # | Name | Date |
|---|---|---|
| 1 | 202347036894-STATEMENT OF UNDERTAKING (FORM 3) [29-05-2023(online)].pdf | 2023-05-29 |
| 2 | 202347036894-Sequence Listing in txt [29-05-2023(online)].txt | 2023-05-29 |
| 3 | 202347036894-Sequence Listing in PDF [29-05-2023(online)].pdf | 2023-05-29 |
| 4 | 202347036894-PRIORITY DOCUMENTS [29-05-2023(online)].pdf | 2023-05-29 |
| 5 | 202347036894-POWER OF AUTHORITY [29-05-2023(online)].pdf | 2023-05-29 |
| 6 | 202347036894-FORM 1 [29-05-2023(online)].pdf | 2023-05-29 |
| 7 | 202347036894-FIGURE OF ABSTRACT [29-05-2023(online)].pdf | 2023-05-29 |
| 8 | 202347036894-DRAWINGS [29-05-2023(online)].pdf | 2023-05-29 |
| 9 | 202347036894-DECLARATION OF INVENTORSHIP (FORM 5) [29-05-2023(online)].pdf | 2023-05-29 |
| 10 | 202347036894-COMPLETE SPECIFICATION [29-05-2023(online)].pdf | 2023-05-29 |
| 11 | 202347036894-FORM 18 [30-05-2023(online)].pdf | 2023-05-30 |
| 12 | 202347036894-Proof of Right [31-05-2023(online)].pdf | 2023-05-31 |
| 13 | 202347036894.pdf | 2023-06-18 |
| 14 | 202347036894-FORM-26 [25-10-2023(online)].pdf | 2023-10-25 |
| 15 | 202347036894-FORM 3 [28-11-2023(online)].pdf | 2023-11-28 |
| 16 | 202347036894-FER.pdf | 2024-12-17 |
| 17 | 202347036894-FORM-26 [17-02-2025(online)].pdf | 2025-02-17 |
| 18 | 202347036894-FORM 3 [17-02-2025(online)].pdf | 2025-02-17 |
| 19 | 202347036894-RELEVANT DOCUMENTS [24-03-2025(online)].pdf | 2025-03-24 |
| 1 | SearchstrategyE_28-11-2024.pdf |